Final Quarter Of P&G CEO Taylor’s Tenure Could Become Stormy With Headwinds From Rising Costs
Executive Summary
P&G’s health care sector’s net sales grew 18% in its latest quarter. Continued growth across its sectors is critical in the face of expected $1.8bn in headwinds from commodity and freight costs in its FY2022.
You may also be interested in...
P&G Among US Firms Asked To Explain How, Why Supply Chain Problems Cause Consumer Hardships
Procter & Gamble and Amazon are among nine companies FTC ordered to provide detailed information to help the agency identify causes behind ongoing supply chain disruptions. Chairwoman Khan says the information should “shed light on market conditions and business practices that may have worsened these disruptions.”
P&G Increasing US Product Prices More Broadly With Commodity Headwinds Still Strong
P&G raises prices on 9 of its 10 US product categories, rolling out increases in grooming, skin care and oral care products now. High commodity costs prompted it to increase its outlook for headwinds of $2.1bn for its FY2022.
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.